Novo Nordisk AS (NONOF)
105.00
+2.16
(+2.10%)
USD |
OTCM |
Nov 22, 16:00
Novo Nordisk Enterprise Value: 463.86B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 463.86B |
| November 21, 2024 | 454.26B |
| November 20, 2024 | 466.04B |
| November 19, 2024 | 447.01B |
| November 18, 2024 | 447.00B |
| November 15, 2024 | 451.42B |
| November 14, 2024 | 467.39B |
| November 13, 2024 | 463.07B |
| November 12, 2024 | 465.79B |
| November 11, 2024 | 476.37B |
| November 08, 2024 | 489.23B |
| November 07, 2024 | 469.04B |
| November 06, 2024 | 489.46B |
| November 05, 2024 | 469.92B |
| November 04, 2024 | 485.90B |
| November 01, 2024 | 493.68B |
| October 31, 2024 | 482.38B |
| October 30, 2024 | 490.39B |
| October 29, 2024 | 490.18B |
| October 28, 2024 | 500.82B |
| October 25, 2024 | 509.97B |
| October 24, 2024 | 513.58B |
| October 23, 2024 | 505.64B |
| October 22, 2024 | 518.03B |
| October 21, 2024 | 527.49B |
| Date | Value |
|---|---|
| October 18, 2024 | 520.24B |
| October 17, 2024 | 512.24B |
| October 16, 2024 | 514.74B |
| October 15, 2024 | 541.17B |
| October 14, 2024 | 529.38B |
| October 11, 2024 | 537.26B |
| October 10, 2024 | 521.40B |
| October 09, 2024 | 511.38B |
| October 08, 2024 | 512.49B |
| October 07, 2024 | 522.52B |
| October 04, 2024 | 504.88B |
| October 03, 2024 | 504.87B |
| October 02, 2024 | 520.40B |
| October 01, 2024 | 523.69B |
| September 30, 2024 | 516.30B |
| September 27, 2024 | 527.93B |
| September 26, 2024 | 568.91B |
| September 25, 2024 | 555.60B |
| September 24, 2024 | 568.95B |
| September 23, 2024 | 553.37B |
| September 20, 2024 | 560.70B |
| September 19, 2024 | 591.87B |
| September 18, 2024 | 593.06B |
| September 17, 2024 | 585.63B |
| September 16, 2024 | 613.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
112.01B
Minimum
Mar 23 2020
665.94B
Maximum
Jun 25 2024
298.93B
Average
245.54B
Median
Nov 17 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 737.78B |
| Genmab AS | 10.52B |
| Ascendis Pharma AS | 7.940B |
| Galecto Inc | -12.28M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 4.023B |
| Revenue (Quarterly) | 10.51B |
| Total Expenses (Quarterly) | 5.525B |
| EPS Diluted (Quarterly) | 0.9019 |
| Gross Profit Margin (Quarterly) | 84.14% |
| Profit Margin (Quarterly) | 38.28% |
| Earnings Yield | 2.94% |
| Operating Earnings Yield | 3.67% |
| Normalized Earnings Yield | 2.939 |